DK2780368T3 - COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A - Google Patents
COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A Download PDFInfo
- Publication number
- DK2780368T3 DK2780368T3 DK12791657.5T DK12791657T DK2780368T3 DK 2780368 T3 DK2780368 T3 DK 2780368T3 DK 12791657 T DK12791657 T DK 12791657T DK 2780368 T3 DK2780368 T3 DK 2780368T3
- Authority
- DK
- Denmark
- Prior art keywords
- activin
- gdf8
- antigen
- antibody
- ser
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161559175P | 2011-11-14 | 2011-11-14 | |
| US201261607024P | 2012-03-06 | 2012-03-06 | |
| US201261661451P | 2012-06-19 | 2012-06-19 | |
| PCT/US2012/064911 WO2013074557A1 (en) | 2011-11-14 | 2012-11-14 | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2780368T3 true DK2780368T3 (en) | 2018-02-05 |
Family
ID=47228083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12791657.5T DK2780368T3 (en) | 2011-11-14 | 2012-11-14 | COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A |
Country Status (19)
| Country | Link |
|---|---|
| US (7) | US8871209B2 (enExample) |
| EP (1) | EP2780368B1 (enExample) |
| JP (1) | JP6177249B2 (enExample) |
| KR (1) | KR102048189B1 (enExample) |
| AU (1) | AU2012339722B2 (enExample) |
| CA (1) | CA2855822C (enExample) |
| CY (1) | CY1119994T1 (enExample) |
| DK (1) | DK2780368T3 (enExample) |
| ES (1) | ES2663946T3 (enExample) |
| HR (1) | HRP20180201T1 (enExample) |
| HU (1) | HUE038570T2 (enExample) |
| LT (1) | LT2780368T (enExample) |
| MX (1) | MX350355B (enExample) |
| PL (1) | PL2780368T3 (enExample) |
| PT (1) | PT2780368T (enExample) |
| RS (1) | RS56796B1 (enExample) |
| SI (1) | SI2780368T1 (enExample) |
| SM (1) | SMT201800092T1 (enExample) |
| WO (1) | WO2013074557A1 (enExample) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| CA2808382A1 (en) | 2010-08-16 | 2012-02-23 | Amgen Inc. | Antibodies that bind myostatin, compositions and methods |
| JP6177249B2 (ja) * | 2011-11-14 | 2017-08-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｇｄｆ８及び／又はアクチビンａに特異的に拮抗することによって筋肉量及び筋力を増加させる組成物及び方法 |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| HUE052232T2 (hu) | 2013-05-06 | 2021-04-28 | Scholar Rock Inc | Készítmények és eljárások növekedési faktor modulálására |
| TW201920262A (zh) * | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| WO2015195094A1 (en) * | 2014-06-17 | 2015-12-23 | Ember Therapeutics, Inc. | Anti-activin and nati-myostatin antibodies and methods of using the same |
| US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| TW201628649A (zh) | 2014-10-09 | 2016-08-16 | 再生元醫藥公司 | 減少醫藥調配物中微可見顆粒之方法 |
| US10307480B2 (en) * | 2014-11-06 | 2019-06-04 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| EA039118B1 (ru) * | 2015-04-01 | 2021-12-07 | Ридженерон Фармасьютикалз, Инк. | Способ лечения прогрессирующей оссифицирующей фибродисплазии |
| WO2016168613A1 (en) * | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| SI3286206T1 (sl) | 2015-04-22 | 2021-07-30 | Biogen Ma Inc. | Novi hibridni proteini ligandske pasti actriib za zdravljenje bolezni zaradi izgube mišične mase |
| TWI870789B (zh) | 2015-08-04 | 2025-01-21 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| PT3922645T (pt) | 2015-09-15 | 2025-05-29 | Scholar Rock Inc | ¿anticorpos anti-pró-miostatina/miostatina latente e suas utilizações |
| CN115814077A (zh) | 2016-01-08 | 2023-03-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| PL3365368T3 (pl) | 2016-03-11 | 2023-08-21 | Scholar Rock, Inc. | Immunoglobuliny wiążące tgfbeta1 i ich zastosowanie |
| KR20230041834A (ko) | 2016-08-16 | 2023-03-24 | 리제너론 파아마슈티컬스, 인크. | 혼합물로부터 개별 항체들을 정량하는 방법 |
| EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| CN119492842A (zh) | 2016-10-25 | 2025-02-21 | 里珍纳龙药品有限公司 | 用于色谱数据分析的方法和系统 |
| CN119241685A (zh) | 2016-11-10 | 2025-01-03 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| WO2018129329A1 (en) | 2017-01-06 | 2018-07-12 | Scholar Rock, Inc. | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF |
| BR112020000127A2 (pt) | 2017-07-06 | 2020-07-07 | Regeneron Pharmaceuticals, Inc. | método para selecionar um hidrolisado de soja, e, glicoproteína |
| CN118416215A (zh) | 2017-09-19 | 2024-08-02 | 里珍纳龙药品有限公司 | 减少粒子形成的方法以及由其形成的组合物 |
| CN111801112A (zh) | 2017-11-09 | 2020-10-20 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| BR112020010615A2 (pt) | 2017-12-22 | 2020-10-27 | Regeneron Pharmaceuticals, Inc. | produto farmacêutico proteico, método e sistema para caracterizar impurezas de produto farmacêutico proteico e de fármaco de baixo peso molecular, método para produzir um anticorpo, anticorpo, e, usos do método e do sistema |
| KR20200109330A (ko) | 2018-01-12 | 2020-09-22 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법 |
| MX2020008095A (es) | 2018-01-31 | 2020-09-24 | Regeneron Pharma | Sistemas y métodos para caracterizar variantes de tamaño y carga de impurezas de productos farmacológicos. |
| TWI786265B (zh) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| KR20200127979A (ko) | 2018-02-28 | 2020-11-11 | 리제너론 파마슈티칼스 인코포레이티드 | 바이러스 오염물질을 확인하기 위한 시스템 및 방법 |
| KR20200128125A (ko) | 2018-03-01 | 2020-11-11 | 리제너론 파아마슈티컬스, 인크. | 신체 조성을 변경하기 위한 방법 |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| CA3246952A1 (en) | 2018-03-19 | 2025-10-31 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| LT3773713T (lt) | 2018-04-06 | 2025-08-25 | Regeneron Pharmaceuticals, Inc. | Leptino receptoriaus agonistinis antikūnas, skirtas kaulų masės didinimui subjektui, kuriam pasireiškia medžiagų apykaitos sutrikimas arba hipoleptinemija |
| WO2019217715A1 (en) | 2018-05-09 | 2019-11-14 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| TWI853823B (zh) | 2018-07-02 | 2024-09-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| US12252531B2 (en) | 2018-07-11 | 2025-03-18 | Scholar Rock, Inc. | Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitors |
| US20210340238A1 (en) | 2018-07-11 | 2021-11-04 | Scholar Rock, Inc. | TGFß1 INHIBITORS AND USE THEREOF |
| HRP20212034T1 (hr) | 2018-07-11 | 2022-04-01 | Scholar Rock, Inc. | Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe |
| CN120795059A (zh) | 2018-08-27 | 2025-10-17 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| US11754569B2 (en) | 2018-08-30 | 2023-09-12 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| MX2021007394A (es) * | 2018-12-18 | 2021-07-15 | Regeneron Pharma | Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a. |
| PL3857237T3 (pl) | 2019-01-16 | 2023-07-10 | Regeneron Pharmaceuticals, Inc. | Sposoby charakteryzowania mostka disiarczkowego |
| EP3934620A1 (en) | 2019-03-05 | 2022-01-12 | Regeneron Pharmaceuticals, Inc. | Human serum albumin in formulations |
| AU2020275406A1 (en) | 2019-05-13 | 2021-11-18 | Regeneron Pharmaceuticals, Inc. | Improved competitive ligand binding assays |
| IL291020B2 (en) | 2019-09-24 | 2025-04-01 | Regeneron Pharma | Systems and methods for use in chromatography and regeneration |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| MY207613A (en) | 2019-11-25 | 2025-03-06 | Regeneron Pharma | Sustained release formulations using non-aqueous emulsions |
| CA3167427A1 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock, Inc. | Tgfb inhibitors and use thereof |
| AU2021205440A1 (en) | 2020-01-11 | 2022-09-01 | Scholar Rock,Inc. | TGF-beta inhibitors and use thereof |
| US11835527B2 (en) | 2020-01-21 | 2023-12-05 | Regeneron Pharmaceuticals, Inc. | Deglycosylation methods for electrophoresis of glycosylated proteins |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| CA3176735A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Activin receptor type ii chimeras and methods of use thereof |
| IL300828A (en) | 2020-08-31 | 2023-04-01 | Regeneron Pharma | Asparagine feeding strategies to improve cell culture performance and reduce asparagine sequence variants |
| MX2023006077A (es) | 2020-11-25 | 2023-06-06 | Regeneron Pharma | Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa. |
| US12350374B2 (en) | 2020-12-17 | 2025-07-08 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| TW202233827A (zh) | 2021-01-20 | 2022-09-01 | 美商再生元醫藥公司 | 改良細胞培養中蛋白質效價的方法 |
| AR125585A1 (es) | 2021-03-03 | 2023-08-02 | Regeneron Pharma | Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| CA3211302A1 (en) | 2021-03-26 | 2022-09-29 | Ross Kenyon | Methods and systems for developing mixing protocols |
| BR112023024984A2 (pt) | 2021-06-01 | 2024-02-20 | Regeneron Pharma | Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit |
| WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| TW202326138A (zh) | 2021-09-08 | 2023-07-01 | 美商再生元醫藥公司 | 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法 |
| CA3232463A1 (en) | 2021-09-20 | 2023-03-23 | Philip Mellors | Methods of controlling antibody heterogeneity |
| JP2024538673A (ja) | 2021-10-07 | 2024-10-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ｐＨモデリング及び制御のシステム及び方法 |
| KR20240090312A (ko) | 2021-10-07 | 2024-06-21 | 리제너론 파아마슈티컬스, 인크. | Ph 미터 보정 및 교정 |
| MX2024005090A (es) | 2021-10-26 | 2024-07-19 | Regeneron Pharma | Sistemas y metodos para generar agua de laboratorio y distribuir agua de laboratorio a diferentes temperaturas. |
| EP4493921A1 (en) | 2022-03-18 | 2025-01-22 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
| KR20250075642A (ko) | 2022-09-21 | 2025-05-28 | 리제너론 파아마슈티컬스, 인크. | 비만, 당뇨병 및 간 기능 장애를 치료하는 방법 |
| CN120418653A (zh) | 2022-12-16 | 2025-08-01 | 里珍纳龙药品有限公司 | 评估色谱柱完整性的方法和系统 |
| AU2023413166A1 (en) | 2022-12-22 | 2025-07-03 | Scholar Rock, Inc. | Selective and potent inhibitory antibodies of myostatin activation |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| WO2024158961A1 (en) | 2023-01-25 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| WO2024163708A1 (en) | 2023-02-01 | 2024-08-08 | Regeneron Pharmaceuticals, Inc. | Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis |
| US20240280551A1 (en) | 2023-02-22 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | System suitability parameters and column aging |
| TW202508625A (zh) | 2023-05-01 | 2025-03-01 | 美商再生元醫藥公司 | 使用苯酚或苯甲醇之多劑量抗體藥物產品 |
| WO2025054406A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| WO2025064403A2 (en) | 2023-09-18 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| CN121925272A (zh) | 2023-09-29 | 2026-04-24 | 瑞泽恩制药公司 | 利用受控成核进行冻干 |
| WO2025085594A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| AU2024373307A1 (en) | 2023-11-02 | 2026-05-14 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
| WO2026025028A1 (en) | 2024-07-26 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Methods of making ultra-high concentrated protein formulations using lyophilization |
| WO2026060350A1 (en) | 2024-09-13 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods |
| WO2026076201A2 (en) | 2024-10-03 | 2026-04-09 | Regeneron Pharmaceuticals, Inc. | Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools |
| WO2026080597A1 (en) | 2024-10-08 | 2026-04-16 | Regeneron Pharmaceuticals, Inc. | Sustained delivery of biologics and non-aqueous manufacture of same |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| ES2201076T3 (es) | 1993-03-19 | 2004-03-16 | The Johns Hopkins University School Of Medicine | Factor-8 de diferenciacion del crecimiento. |
| DE69941116D1 (de) | 1998-05-06 | 2009-08-27 | Metamorphix Inc | G von gdf-8 |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| SK722002A3 (en) | 1999-07-20 | 2003-02-04 | Pharmexa As | Method for down-regulating GDF-8 activity |
| US6670140B2 (en) * | 2001-03-06 | 2003-12-30 | The Procter & Gamble Company | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| JP5110877B2 (ja) | 2003-06-02 | 2012-12-26 | ワイス・エルエルシー | 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用 |
| CN1902221A (zh) | 2003-12-31 | 2007-01-24 | 先灵-普劳有限公司 | 基于中和表位的生长增强疫苗 |
| US7456149B2 (en) | 2004-03-02 | 2008-11-25 | Acceleron Pharma, Inc. | ALK7 and myostatin inhibitors and uses thereof |
| US20070178095A1 (en) | 2004-03-23 | 2007-08-02 | Eli Lilly And Company | Anti-myostatin antibodies |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| MX2007000976A (es) | 2004-08-12 | 2007-04-10 | Wyeth Corp | Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion. |
| NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| EP1877075A4 (en) | 2005-04-25 | 2008-07-30 | Pfizer | ANTIBODY TO MYOSTATIN |
| BRPI0611069A2 (pt) | 2005-05-06 | 2010-11-09 | Zymogenetics Inc | anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma |
| EP1773041A1 (en) | 2005-07-21 | 2007-04-11 | Chao-Hung Wu | Audio/video data transmission system using the internet to interconnect telephones |
| PL2407486T3 (pl) | 2005-08-19 | 2018-05-30 | Wyeth Llc | Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8 |
| ES2533464T3 (es) | 2005-10-06 | 2015-04-10 | Eli Lilly And Company | Anticuerpos anti-miostatina |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| EP1968621A2 (en) | 2005-12-06 | 2008-09-17 | Amgen Inc. | Uses of myostatin antagonists |
| NZ587107A (en) | 2006-06-02 | 2012-05-25 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| CA2693378C (en) | 2006-08-03 | 2020-04-14 | Myostin Therapeutics Pty Ltd | Myostatin antagonists |
| PL2066695T3 (pl) | 2006-09-05 | 2013-08-30 | Lilly Co Eli | Przeciwciała przeciwko miostatynie |
| CL2007002567A1 (es) * | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| US7947646B2 (en) | 2007-03-06 | 2011-05-24 | Amgen Inc. | Variant activin receptor polypeptides |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| AR069165A1 (es) | 2007-11-05 | 2010-01-06 | Novartis Ag | Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia |
| TWI626945B (zh) | 2008-08-14 | 2018-06-21 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| AR074777A1 (es) | 2008-12-19 | 2011-02-09 | Glaxo Group Ltd | Proteinas de union a antigeno |
| AU2010204985A1 (en) | 2009-01-13 | 2011-08-04 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| CA2993053A1 (en) | 2009-04-27 | 2010-11-04 | Novartis Ag | Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth |
| LT2975051T (lt) | 2009-06-26 | 2021-07-12 | Regeneron Pharmaceuticals, Inc. | Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu |
| EP3332796A1 (en) * | 2009-11-17 | 2018-06-13 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| AR081556A1 (es) | 2010-06-03 | 2012-10-03 | Glaxo Group Ltd | Proteinas de union al antigeno humanizadas |
| CA2808382A1 (en) | 2010-08-16 | 2012-02-23 | Amgen Inc. | Antibodies that bind myostatin, compositions and methods |
| KR20130132824A (ko) | 2010-11-08 | 2013-12-05 | 악셀레론 파마 인코포레이티드 | Actriia 결합제 및 이의 용도 |
| JP6177249B2 (ja) | 2011-11-14 | 2017-08-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｇｄｆ８及び／又はアクチビンａに特異的に拮抗することによって筋肉量及び筋力を増加させる組成物及び方法 |
| GR1007832B (el) | 2011-11-21 | 2013-02-14 | Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
| MY177331A (en) | 2012-06-15 | 2020-09-12 | Pfizer | Improved antagonist antibodies against gdf-8 and uses therefor |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| SG11201505960VA (en) | 2013-02-01 | 2015-08-28 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject |
| TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| CA2918300A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Methods of treating sporadic inclusion body myositis |
| US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| WO2016168613A1 (en) | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| US20180008672A1 (en) | 2016-07-08 | 2018-01-11 | Regeneron Pharmaceuticals, Inc. | Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension |
| KR20200128125A (ko) | 2018-03-01 | 2020-11-11 | 리제너론 파아마슈티컬스, 인크. | 신체 조성을 변경하기 위한 방법 |
-
2012
- 2012-11-14 JP JP2014541413A patent/JP6177249B2/ja active Active
- 2012-11-14 ES ES12791657.5T patent/ES2663946T3/es active Active
- 2012-11-14 KR KR1020147016067A patent/KR102048189B1/ko active Active
- 2012-11-14 HR HRP20180201TT patent/HRP20180201T1/hr unknown
- 2012-11-14 DK DK12791657.5T patent/DK2780368T3/en active
- 2012-11-14 AU AU2012339722A patent/AU2012339722B2/en active Active
- 2012-11-14 WO PCT/US2012/064911 patent/WO2013074557A1/en not_active Ceased
- 2012-11-14 CA CA2855822A patent/CA2855822C/en active Active
- 2012-11-14 RS RS20180105A patent/RS56796B1/sr unknown
- 2012-11-14 SI SI201231245T patent/SI2780368T1/en unknown
- 2012-11-14 LT LTEP12791657.5T patent/LT2780368T/lt unknown
- 2012-11-14 HU HUE12791657A patent/HUE038570T2/hu unknown
- 2012-11-14 EP EP12791657.5A patent/EP2780368B1/en active Active
- 2012-11-14 US US13/676,233 patent/US8871209B2/en active Active
- 2012-11-14 PL PL12791657T patent/PL2780368T3/pl unknown
- 2012-11-14 SM SM20180092T patent/SMT201800092T1/it unknown
- 2012-11-14 MX MX2014005865A patent/MX350355B/es active IP Right Grant
- 2012-11-14 PT PT127916575T patent/PT2780368T/pt unknown
-
2014
- 2014-09-25 US US14/496,941 patent/US20150010568A1/en not_active Abandoned
-
2016
- 2016-03-22 US US15/077,662 patent/US20170008956A1/en not_active Abandoned
- 2016-09-30 US US15/282,489 patent/US20170226197A1/en not_active Abandoned
-
2018
- 2018-02-09 US US15/893,480 patent/US10400036B2/en active Active
- 2018-03-01 CY CY20181100259T patent/CY1119994T1/el unknown
-
2019
- 2019-07-17 US US16/514,858 patent/US11655291B2/en active Active
-
2023
- 2023-04-17 US US18/135,608 patent/US20240117027A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11655291B2 (en) | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or activin A | |
| TWI604852B (zh) | 藉由拮抗ｉｌ－６受體抑制腫瘤生長之方法 | |
| US20250109191A1 (en) | Methods for altering body composition by administering a gdf8 inhibitor and an activin a inhibitor | |
| HK1202559B (en) | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a | |
| EA046653B1 (ru) | Способы изменения состава тела | |
| HK1197681A (en) | Methods of inhibiting tumor growth by antagonizing il-6 receptor |